Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of JS005 via Pre-filled Syringe vs Automatic Syringe in Healthy Volunteers
NCT06732973Phase 1Completed
- Sponsor
- Shanghai Junshi Biosciences Co., Ltd.
- Start
- Dec 2024
- Primary completion
- Jun 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of roconkibart (2 arms), sponsored by Shanghai Junshi Biosciences Co., Ltd. Primary endpoints: Area Under the Concentration-Time Curve From Time Zero to the Last Quantifiable Concentration at 85 days, Maximum Observed Plasma Concentration at 85 days and 1 more. Started Dec 2024; status: completed.
02
Drugs
roconkibart
Beyond the preview
Go deeper on NCT06732973.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06732973.